P3 Health Partners Inc. (PIII)

NEUTRAL

HealthcareMedical Care FacilitiesUnited States

基本面

价格

$10.07

市值

$2.04B

Yahoo Finance TradingView 新闻官网

第一部分 · 这家公司值多少

概览

P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. The company was founded in 2020 and is based in Henderson, Nevada.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

资产负债表与流动性

营收

$1.50B

最近12个月（截至2026/6/30）

净利润

$-98M

最近12个月（截至2026/6/30）

自由现金流

股东权益合计

$-155M

负债合计

$797M

流动比率

0.46

利息覆盖率

2.44

债务/EBITDA

每股收益

营收与净利润

自由现金流

收入构成

历史财务表

利润率变化

债务变化

债务负担有多重

增长一览表

增长 — 营业收入

公允价值估算

General case被低估

公允价值

$18.00

当前价格

$10.07

安全边际

+44.1%

公允价值区间

$17.10 - $18.90

估算方法

Analyst price target:$18.00

Discounted cash flow (DCF):Not enough data to compute it

Earnings multiple (P/E):Not enough data to compute it

Graham growth formula:Not enough data to compute it

Earnings power value (EPV):Not enough data to compute it

Justified P/B:$15.59

Dividend discount (Gordon):Not enough data to compute it

P/FFO, funds from operations:Not enough data to compute it

Mid-cycle earnings:Not enough data to compute it

Revenue multiple:Not enough data to compute it

分析师共识:强力买入 (6B / 2H / 0S)

最近财报超预期:+67.41%

估值指标

市盈率（P/E）

ROE

95.3%

市净率（P/B）

0.54

P/FCF

毛利率

ROIC

-44.2%

盈利能力雷达图

Value Creation (Economic Moat)

ROIC

-44.2%

WACC

14.7%

ROIC − WACC

-58.9 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

基本面分析标准

通过（6）

P/B Ratio 0.54
Interest Coverage
ROE 10.3%
Revenue Growth 5Y 24.6%
Analyst Consensus 75% Buy
Net Margin Trend -6.6% vs -10.0%

未通过（11）

EPS shows upward trend
Price CAGR -50.65%
ROIC -44.2%
Operating Margin -9.9%
Current Ratio
Return on Tangible Assets
Low reliance on intangibles
DCF valuation (Unknown)
Earnings Surprise avg -4.8%
Share Dilution 30.1%
Piotroski F-Score 2/9

不可用（10）

Gross Margin NaN%
P/FCF NaN
Dividend Payout NaN%
Debt/Equity ratio
Positive Free Cash Flow
CapEx intensity
Debt/EBITDA
Price below Graham Number
PEG Ratio (need PE > 0 and growth > 0)
Earnings Quality (OCF/Net Income)

Piotroski F-评分

2/9

存在严重财务隐患

score

criteria

盈利质量

低质量：需深入审查会计处理

股权稀释

30.1%

正在发行新股，稀释所有权

公司治理

管理团队

姓名	职位	年龄
Dr. Aric Coffman M.D.	CEO, President & Director	51
Dr. Amir Bacchus M.B.A., M.D.	Co-Founder, Chief Medical Officer & Director	60
Mr. Leif Pedersen	Chief Financial Officer	49
Mr. William Bettermann	Executive VP & COO	-
Mr. Devery Goodey	Senior Vice President of Technology	-
Ms. Sarah Bussmann B.S.N., CRNI, M.H.A., R.N.	Chief Administrative Officer	-

第二部分 · 价格与买入时机

这一部分不判断公司是否值得拥有：它帮助你在基本面说服你之后，选择何时买入。包含：技术分析、潜力、历史回撤、Gamma 敞口。

Latest News

Recent headlines for PIII, sourced from Markets Gazette.

No recent news for PIII.